The U.S. Food and Drug Administration has granted orphan drug status to Prometic Life Sciences’ Ryplazim (plasminogen) as a treatment for idiopathic pulmonary fibrosis. Fewer than 200,000 Americans have IPF, which makes it eligible for orphan status. The designation gives companies incentives to develop drugs for the small markets typical…
News
Synairgen announced the revision in the terms of its collaboration with Pharmaxis to advance the development of its Lysyl Oxidase type 2 (LOXL2) program for the treatment of fibrotic conditions, including pulmonary fibrosis (PF). Fibrosis develops due to abnormal wound healing, and is characterized by a buildup of scar…
The management of patients with idiopathic pulmonary fibrosis (IPF) and lung cancer should follow the premise “first, do no harm,” researchers argue in the journal The Lancet Respiratory Medicine. Their commentary, “Patients with IPF and lung cancer: diagnosis and management,” spotlights the fact that — despite lung…
Doctors may be able to use six energy-storing substances known as lipids to diagnose and track the progression of idiopathic pulmonary fibrosis, a Chinese study reports. The research, “Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics,” appeared in the journal BMC Pulmonary…
A real-world study in Britain confirms that Ofev (nintedanib) is a safe and effective treatment for idiopathic pulmonary fibrosis, or IPF. The research, “Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres,” was published in the journal Clinical and Translational…
British regulators have paved the way for people with severe cases of pulmonary fibrosis to gain access to Prometic Life Sciences’ tissue-scarring therapy PBI-4050 before it is approved. The step the regulators took was to designate PBI-4050 a Promising Innovative Medicine for idiopathic pulmonary fibrosis. The next step would be…
Researchers have found another piece in the molecular puzzle of changes leading to pulmonary fibrosis — a cell signaling factor. It offers scientists a new target for developing lung-scarring treatments. Lung damage leads to the production of a protein that attracts immune cells to the area. Without this signaling, mice…
A factor called Krüpple-like-factor 4, or KLF4, treated lung fibrosis in a mouse model of idiopathic pulmonary fibrosis (IPF) by preventing epithelial cells of the lung from moving into a fibrosis-promoting state, researchers in China report, suggesting its potential as an IPF therapy. The study “Krüpple-like-factor 4 Attenuates Lung…
Thyroid hormone, delivered through aerosol inhalation, helped to resolve lung scarring in a mouse model of idiopathic pulmonary fibrosis (IPF), according to research published in the journal Nature Medicine. The study provides evidence that lung fibrosis is a disease caused — at least partly — by abnormalities in metabolic processes…
An anti-inflammatory agent known as ulinastatin decreases pulmonary fibrosis, and at high doses may protect against lung tissue scarring, a study in rats showed. The research, “Therapeutic effect of ulinastatin on pulmonary fibrosis via downregulation of TGF‑β1, TNF‑α and NF‑κB,” was published in the journal Molecular Medicine Reports.
